Novartis acquired Avidity Biosciences to aggressively expand its footprint in specialized neuroscience and establish undisputed leadership in treating severe neuromuscular conditions such as Duchenne muscular dystrophy and myotonic dystrophy. By absorbing Avidity's proprietary delivery platform, the pharmaceutical titan secured groundbreaking late-stage clinical assets designed to unlock multi-billion-dollar market opportunities and accelerate innovative genetic medicines toward global commercialization before the end of the decade.